{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:19:40Z","timestamp":1791825580118,"version":"4.3.4"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,12,21]],"date-time":"2016-12-21T00:00:00Z","timestamp":1482278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,12,21]],"date-time":"2016-12-21T00:00:00Z","timestamp":1482278400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Acute lymphoblastic leukemia (ALL) is a heterogeneous disease, and the long-term survival varies with different ages. We performed a retrospective analysis of 122 newly diagnosed adults with standard-risk ALL treated with <jats:italic>Escherichia coli<\/jats:italic> asparaginase (<jats:italic>E. coli<\/jats:italic>-asparaginase, n\u2009=\u200950) and polyethylene glycol-conjugated asparaginase (PEG-asparaginase, n\u2009=\u200972). No treatment-related mortality (TRM) occurred in the <jats:italic>E. coli<\/jats:italic>-asparaginase group, and 3 TRM events occurred in the PEG-asparaginase group without relation to asparaginase. In addition, 22 (44.0%) and 48 (66.7%) patients achieved a complete response (CR) on day 14 in the <jats:italic>E. coli<\/jats:italic>-asparaginase and PEG-asparaginase groups, respectively (<jats:italic>P<\/jats:italic>\u2009=\u20090.032). No different 5-year event-free survival (EFS) or overall survival (OS) rate (<jats:italic>P<\/jats:italic>\u2009=\u20090.632 and 0.769) was observed. Multivariate analysis revealed later CR (<jats:italic>P<\/jats:italic>\u2009=\u20090.008) and older age (<jats:italic>P<\/jats:italic>\u2009=\u20090.049) as adverse prognostic factors for both EFS and OS. In addition, we specifically monitored the known adverse effects of asparaginase, and no asparaginase-related death was observed. Allergy occurred in 9 patients using <jats:italic>E. coli<\/jats:italic>-asparaginase, and no patient in the PEG-asparaginase group suffered from allergies (<jats:italic>P<\/jats:italic>\u2009&lt;0.001). The incidence of other asparaginase-related toxicities was similar. We conclude that PEG-asparaginase can be safely and effectively used as asparaginase in adults with newly diagnosed standard-risk ALL.<\/jats:p>","DOI":"10.1038\/srep39463","type":"journal-article","created":{"date-parts":[[2016,12,21]],"date-time":"2016-12-21T10:42:47Z","timestamp":1482316967000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Use of PEG-asparaginase in newly diagnosed adults with standard-risk acute lymphoblastic leukemia compared with E. coli-asparaginase: a retrospective single-center study"],"prefix":"10.1038","volume":"6","author":[{"given":"Wen-jian","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-da","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-yuan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-cheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-hua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,12,21]]},"reference":[{"key":"BFsrep39463_CR1","doi-asserted-by":"publisher","first-page":"168","DOI":"10.3109\/10428194.2010.537796","volume":"52","author":"H van den Berg","year":"2011","unstructured":"van den Berg, H. Asparaginase revisited. Leukemia & lymphoma 52, 168\u2013178, doi: 10.3109\/10428194.2010.537796 (2011).","journal-title":"Leukemia & lymphoma"},{"key":"BFsrep39463_CR2","first-page":"4363","volume":"49","author":"BL Asselin","year":"1989","unstructured":"Asselin, B. L. et al. In vitro and in vivo killing of acute lymphoblastic leukemia cells by L-asparaginase. Cancer research 49, 4363\u20134368 (1989).","journal-title":"Cancer research"},{"key":"BFsrep39463_CR3","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1002\/1097-0142(19950301)75:5<1176::AID-CNCR2820750519>3.0.CO;2-Y","volume":"75","author":"LJ Ettinger","year":"1995","unstructured":"Ettinger, L. J., Kurtzberg, J., Voute, P. A., Jurgens, H. & Halpern, S. L. An open-label, multicenter study of polyethylene glycol-L-asparaginase for the treatment of acute lymphoblastic leukemia. Cancer 75, 1176\u20131181 (1995).","journal-title":"Cancer"},{"key":"BFsrep39463_CR4","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1046\/j.1365-2141.2000.02187.x","volume":"110","author":"HJ Muller","year":"2000","unstructured":"Muller, H. J. et al. Pegylated asparaginase (Oncaspar) in children with ALL: drug monitoring in reinduction according to the ALL\/NHL-BFM 95 protocols. British journal of haematology 110, 379\u2013384 (2000).","journal-title":"British journal of haematology"},{"key":"BFsrep39463_CR5","first-page":"24","volume":"91","author":"C Rizzari","year":"2006","unstructured":"Rizzari, C. et al. A pharmacological study on pegylated asparaginase used in front-line treatment of children with acute lymphoblastic leukemia. Haematologica 91, 24\u201331 (2006).","journal-title":"Haematologica"},{"key":"BFsrep39463_CR6","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1182\/blood.V99.6.1986","volume":"99","author":"VI Avramis","year":"2002","unstructured":"Avramis, V. I. et al. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children\u2019s Cancer Group study. Blood 99, 1986\u20131994 (2002).","journal-title":"Blood"},{"key":"BFsrep39463_CR7","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1046\/j.1365-2141.2003.04707.x","volume":"123","author":"O Rosen","year":"2003","unstructured":"Rosen, O. et al. Pegylated asparaginase in combination with high-dose methotrexate for consolidation in adult acute lymphoblastic leukaemia in first remission: a pilot study. British journal of haematology 123, 836\u2013841 (2003).","journal-title":"British journal of haematology"},{"key":"BFsrep39463_CR8","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1182\/blood.V85.8.2025.bloodjournal8582025","volume":"85","author":"RA Larson","year":"1995","unstructured":"Larson, R. A. et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood 85, 2025\u20132037 (1995).","journal-title":"Blood"},{"key":"BFsrep39463_CR9","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1016\/0006-2952(69)90375-X","volume":"18","author":"CM Haskell","year":"1969","unstructured":"Haskell, C. M. & Canellos, G. P. l-asparaginase resistance in human leukemia\u2013asparagine synthetase. Biochemical pharmacology 18, 2578\u20132580 (1969).","journal-title":"Biochemical pharmacology"},{"key":"BFsrep39463_CR10","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1146\/annurev.pa.10.040170.002225","volume":"10","author":"DA Cooney","year":"1970","unstructured":"Cooney, D. A. & Handschumacher, R. E. L-asparaginase and L-asparagine metabolism. Annual review of pharmacology 10, 421\u2013440, doi: 10.1146\/annurev.pa.10.040170.002225 (1970).","journal-title":"Annual review of pharmacology"},{"key":"BFsrep39463_CR11","first-page":"727","volume":"18","author":"P Nandy","year":"1998","unstructured":"Nandy, P., Periclou, A. P. & Avramis, V. I. The synergism of 6-mercaptopurine plus cytosine arabinoside followed by PEG-asparaginase in human leukemia cell lines (CCRF\/CEM\/0 and (CCRF\/CEM\/ara-C\/7A) is due to increased cellular apoptosis. Anticancer research 18, 727\u2013737 (1998).","journal-title":"Anticancer research"},{"key":"BFsrep39463_CR12","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1002\/cncr.25489","volume":"117","author":"R Pieters","year":"2011","unstructured":"Pieters, R. et al. L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase. Cancer 117, 238\u2013249, doi: 10.1002\/cncr.25489 (2011).","journal-title":"Cancer"},{"key":"BFsrep39463_CR13","unstructured":"Kurtzberg, J. Asparaginase. In: Holland, J. F., Bast, F. E. I. R. C. Jr. et al.Cancer Medicine. 4th. Vol. 1027\u20131035 (Williams & Wilkens, 1997)."},{"key":"BFsrep39463_CR14","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1007\/s12010-015-1917-3","volume":"178","author":"T Batool","year":"2016","unstructured":"Batool, T., Makky, E. A., Jalal, M. & Yusoff, M. M. A Comprehensive Review on L-Asparaginase and Its Applications. Applied biochemistry and biotechnology 178, 900\u2013923, doi: 10.1007\/s12010-015-1917-3 (2016).","journal-title":"Applied biochemistry and biotechnology"},{"key":"BFsrep39463_CR15","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1200\/JCO.1994.12.4.740","volume":"12","author":"MA Schorin","year":"1994","unstructured":"Schorin, M. A. et al. Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber Cancer Institute\/Children\u2019s Hospital Acute Lymphoblastic Leukemia Consortium Protocol 85-01. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 12, 740\u2013747 (1994).","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"key":"BFsrep39463_CR16","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1002\/1097-0142(197601)37:1<220::AID-CNCR2820370132>3.0.CO;2-W","volume":"37","author":"D Killander","year":"1976","unstructured":"Killander, D. et al. Hypersensitive reactions and antibody formation during L-asparaginase treatment of children and adults with acute leukemia. Cancer 37, 220\u2013228 (1976).","journal-title":"Cancer"},{"key":"BFsrep39463_CR17","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.3109\/10428194.2011.596963","volume":"52","author":"W Stock","year":"2011","unstructured":"Stock, W. et al. Prevention and management of asparaginase\/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel. Leukemia & lymphoma 52, 2237\u20132253, doi: 10.3109\/10428194.2011.596963 (2011).","journal-title":"Leukemia & lymphoma"},{"key":"BFsrep39463_CR18","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/leu.2012.290","volume":"27","author":"E Truelove","year":"2013","unstructured":"Truelove, E., Fielding, A. K. & Hunt, B. J. The coagulopathy and thrombotic risk associated with L-asparaginase treatment in adults with acute lymphoblastic leukaemia. Leukemia 27, 553\u2013559, doi: 10.1038\/leu.2012.290 (2013).","journal-title":"Leukemia"},{"key":"BFsrep39463_CR19","first-page":"2423","volume":"32","author":"VI Avramis","year":"2012","unstructured":"Avramis, V. I. Asparaginases: biochemical pharmacology and modes of drug resistance. Anticancer research 32, 2423\u20132437 (2012).","journal-title":"Anticancer research"},{"key":"BFsrep39463_CR20","doi-asserted-by":"publisher","first-page":"2744","DOI":"10.1182\/blood-2006-07-035006","volume":"109","author":"D Douer","year":"2007","unstructured":"Douer, D. et al. Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia. Blood 109, 2744\u20132750, doi: 10.1182\/blood-2006-07-035006 (2007).","journal-title":"Blood"},{"issue":"7","key":"BFsrep39463_CR21","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1038\/leu.2016.21","volume":"30","author":"M Meggendorfer","year":"2016","unstructured":"Patel, B. et al. Pegylated-asparaginase during induction therapy for adult acute lymphoblastic leukaemia: toxicity data from the UKALL14 trial. Leukemia, doi: 10.1038\/leu.2016.219 (2016).","journal-title":"Leukemia"},{"key":"BFsrep39463_CR22","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.1182\/blood.V99.8.2734","volume":"99","author":"M Duval","year":"2002","unstructured":"Duval, M. et al. Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children\u2019s Leukemia Group phase 3 trial. Blood 99, 2734\u20132739 (2002).","journal-title":"Blood"},{"key":"BFsrep39463_CR23","first-page":"3310","volume":"95","author":"M Schrappe","year":"2000","unstructured":"Schrappe, M. et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. Blood 95, 3310\u20133322 (2000).","journal-title":"Blood"},{"key":"BFsrep39463_CR24","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/sj.leu.2400959","volume":"12","author":"JM Chessells","year":"1998","unstructured":"Chessells, J. M. et al. The impact of age on outcome in lymphoblastic leukaemia; MRC UKALL X and XA compared: a report from the MRC Paediatric and Adult Working Parties. Leukemia 12, 463\u2013473 (1998).","journal-title":"Leukemia"},{"key":"BFsrep39463_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbmt.2005.10.018","volume":"12","author":"T Hahn","year":"2006","unstructured":"Hahn, T. et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in adults: an evidence-based review. Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation 12, 1\u201330, doi: 10.1016\/j.bbmt.2005.10.018 (2006).","journal-title":"Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation"},{"key":"BFsrep39463_CR26","doi-asserted-by":"publisher","first-page":"13","DOI":"10.7326\/0003-4819-115-1-13","volume":"115","author":"MM Horowitz","year":"1991","unstructured":"Horowitz, M. M. et al. Chemotherapy compared with bone marrow transplantation for adults with acute lymphoblastic leukemia in first remission. Annals of internal medicine 115, 13\u201318 (1991).","journal-title":"Annals of internal medicine"},{"key":"BFsrep39463_CR27","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S0140-6736(04)15542-6","volume":"363","author":"AA Ferrando","year":"2004","unstructured":"Ferrando, A. A. et al. Prognostic importance of TLX1 (HOX11) oncogene expression in adults with T-cell acute lymphoblastic leukaemia. Lancet 363, 535\u2013536, doi: 10.1016\/S0140-6736(04)15542-6 (2004).","journal-title":"Lancet"},{"key":"BFsrep39463_CR28","doi-asserted-by":"publisher","first-page":"3760","DOI":"10.1182\/blood-2005-04-1623","volume":"106","author":"JM Rowe","year":"2005","unstructured":"Rowe, J. M. et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII\/ECOG E2993. Blood 106, 3760\u20133767, doi: 10.1182\/blood-2005-04-1623 (2005).","journal-title":"Blood"},{"key":"BFsrep39463_CR29","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.1182\/blood-2006-10-051912","volume":"109","author":"AV Moorman","year":"2007","unstructured":"Moorman, A. V. et al. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII\/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood 109, 3189\u20133197, doi: 10.1182\/blood-2006-10-051912 (2007).","journal-title":"Blood"},{"key":"BFsrep39463_CR30","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1182\/blood-2005-07-2708","volume":"107","author":"M Bruggemann","year":"2006","unstructured":"Bruggemann, M. et al. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood 107, 1116\u20131123, doi: 10.1182\/blood-2005-07-2708 (2006).","journal-title":"Blood"},{"key":"BFsrep39463_CR31","doi-asserted-by":"publisher","first-page":"4164","DOI":"10.1182\/blood-2006-09-045351","volume":"109","author":"M Wetzler","year":"2007","unstructured":"Wetzler, M. et al. Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511. Blood 109, 4164\u20134167, doi: 10.1182\/blood-2006-09-045351 (2007).","journal-title":"Blood"},{"key":"BFsrep39463_CR32","doi-asserted-by":"crossref","unstructured":"DeAngelo, D. J., D., S., Silverman, L. B. et al. A multicenter phase II study using a dose intensified pediatric regimen in adults with untreated acute lymphoblastic leukemia. Blood 110, 2007 (abstr 587) (2007).","DOI":"10.1182\/blood.V110.11.587.587"},{"key":"BFsrep39463_CR33","doi-asserted-by":"publisher","first-page":"367","DOI":"10.2165\/00003088-200544040-00003","volume":"44","author":"VI Avramis","year":"2005","unstructured":"Avramis, V. I. & Panosyan, E. H. Pharmacokinetic\/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future. Clinical pharmacokinetics 44, 367\u2013393, doi: 10.2165\/00003088-200544040-00003 (2005).","journal-title":"Clinical pharmacokinetics"},{"key":"BFsrep39463_CR34","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1038\/sj.leu.2403011","volume":"17","author":"B Wang","year":"2003","unstructured":"Wang, B. et al. Evaluation of immunologic crossreaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients. Leukemia 17, 1583\u20131588, doi: 10.1038\/sj.leu.2403011 (2003).","journal-title":"Leukemia"},{"key":"BFsrep39463_CR35","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1038\/sj.leu.2401162","volume":"12","author":"MH Woo","year":"1998","unstructured":"Woo, M. H. et al. Anti-asparaginase antibodies following E. coli asparaginase therapy in pediatric acute lymphoblastic leukemia. Leukemia 12, 1527\u20131533 (1998).","journal-title":"Leukemia"},{"key":"BFsrep39463_CR36","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1038\/sj.leu.2403351","volume":"18","author":"LJ Hak","year":"2004","unstructured":"Hak, L. J. et al. Asparaginase pharmacodynamics differ by formulation among children with newly diagnosed acute lymphoblastic leukemia. Leukemia 18, 1072\u20131077, doi: 10.1038\/sj.leu.2403351 (2004).","journal-title":"Leukemia"},{"key":"BFsrep39463_CR37","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1002\/pbc.20064","volume":"43","author":"B Zalewska-Szewczyk","year":"2004","unstructured":"Zalewska-Szewczyk, B., Andrzejewski, W. & Bodalski, J. Development of anti-asparaginase antibodies in childhood acute lymphoblastic leukemia. Pediatric blood & cancer 43, 600\u2013602, doi: 10.1002\/pbc.20064 (2004).","journal-title":"Pediatric blood & cancer"},{"key":"BFsrep39463_CR38","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/sj.leu.2401310","volume":"13","author":"MD Amylon","year":"1999","unstructured":"Amylon, M. D. et al. Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study. Leukemia 13, 335\u2013342 (1999).","journal-title":"Leukemia"},{"key":"BFsrep39463_CR39","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1002\/1097-0142(19920701)70:1<201::AID-CNCR2820700131>3.0.CO;2-M","volume":"70","author":"AL Billett","year":"1992","unstructured":"Billett, A. L., Carls, A., Gelber, R. D. & Sallan, S. E. Allergic reactions to Erwinia asparaginase in children with acute lymphoblastic leukemia who had previous allergic reactions to Escherichia coli asparaginase. Cancer 70, 201\u2013206 (1992).","journal-title":"Cancer"},{"key":"BFsrep39463_CR40","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1097\/MPH.0b013e3181483df1","volume":"29","author":"P Wacker","year":"2007","unstructured":"Wacker, P. et al. Allergic reactions to E. coli L-asparaginase do not affect outcome in childhood B-precursor acute lymphoblastic leukemia: a Children\u2019s Oncology Group Study. Journal of pediatric hematology\/oncology 29, 627\u2013632, doi: 10.1097\/MPH.0b013e3181483df1 (2007).","journal-title":"Journal of pediatric hematology\/oncology"},{"key":"BFsrep39463_CR41","doi-asserted-by":"publisher","first-page":"e149","DOI":"10.1002\/phar.1460","volume":"34","author":"LW Buie","year":"2014","unstructured":"Buie, L. W., Moore, J. & van Deventer, H. Successful use of octreotide as a chemoprotectant for prevention of PEG-asparaginase-induced pancreatitis. Pharmacotherapy 34, e149\u2013151, doi: 10.1002\/phar.1460 (2014).","journal-title":"Pharmacotherapy"},{"key":"BFsrep39463_CR42","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1002\/pbc.21037","volume":"49","author":"HM Knoderer","year":"2007","unstructured":"Knoderer, H. M., Robarge, J. & Flockhart, D. A. Predicting asparaginase-associated pancreatitis. Pediatric blood & cancer 49, 634\u2013639, doi: 10.1002\/pbc.21037 (2007).","journal-title":"Pediatric blood & cancer"},{"key":"BFsrep39463_CR43","doi-asserted-by":"crossref","unstructured":"Aldoss, I. et al. Toxicity profile of repeated doses of PEG-asparaginase incorporated into a pediatric-type regimen for adult acute lymphoblastic leukemia. European journal of haematology, doi: 10.1111\/ejh.12600 (2015).","DOI":"10.1111\/ejh.12600"},{"key":"BFsrep39463_CR44","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.3324\/haematol.2014.109413","volume":"99","author":"WH Tong","year":"2014","unstructured":"Tong, W. H. et al. The toxicity of very prolonged courses of PEGasparaginase or Erwinia asparaginase in relation to asparaginase activity, with a special focus on dyslipidemia. Haematologica 99, 1716\u20131721, doi: 10.3324\/haematol.2014.109413 (2014).","journal-title":"Haematologica"},{"key":"BFsrep39463_CR45","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1055\/s-0028-1095058","volume":"2","author":"A Khan","year":"1970","unstructured":"Khan, A., Adachi, M. & Hill, J. M. Potentiation of diabetogenic effect of L-asparaginase by prednisolone. Hormone and metabolic research\u2009=\u2009Hormon- und Stoffwechselforschung\u2009=\u2009Hormones et metabolisme 2, 275\u2013276, doi: 10.1055\/s-0028-1095058 (1970).","journal-title":"Hormone and metabolic research\u2009=\u2009Hormon- und Stoffwechselforschung\u2009=\u2009Hormones et metabolisme"},{"key":"BFsrep39463_CR46","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1055\/s-2003-42647","volume":"23","author":"S Sahoo","year":"2003","unstructured":"Sahoo, S. & Hart, J. Histopathological features of L-asparaginase-induced liver disease. Seminars in liver disease 23, 295\u2013299, doi: 10.1055\/s-2003-42647 (2003).","journal-title":"Seminars in liver disease"},{"key":"BFsrep39463_CR47","first-page":"426","volume":"29","author":"PS Schein","year":"1969","unstructured":"Schein, P. S., Rakieten, N., Gordon, B. M., Davis, R. D. & Rall, D. P. The toxicity of Escherichia coli L-asparaginase. Cancer research 29, 426\u2013434 (1969).","journal-title":"Cancer research"},{"key":"BFsrep39463_CR48","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1517\/14712590802586058","volume":"9","author":"A Zeidan","year":"2009","unstructured":"Zeidan, A., Wang, E. S. & Wetzler, M. Pegasparaginase: where do we stand? Expert opinion on biological therapy 9, 111\u2013119, doi: 10.1517\/14712590802586058 (2009).","journal-title":"Expert opinion on biological therapy"},{"key":"BFsrep39463_CR49","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/S0169-409X(03)00110-8","volume":"55","author":"ML Graham","year":"2003","unstructured":"Graham, M. L. Pegaspargase: a review of clinical studies. Advanced drug delivery reviews 55, 1293\u20131302 (2003).","journal-title":"Advanced drug delivery reviews"},{"key":"BFsrep39463_CR50","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1111\/j.1365-2141.2010.08524.x","volume":"152","author":"RF Grace","year":"2011","unstructured":"Grace, R. F. et al. The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols. British journal of haematology 152, 452\u2013459, doi: 10.1111\/j.1365-2141.2010.08524.x (2011).","journal-title":"British journal of haematology"},{"key":"BFsrep39463_CR51","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.3324\/haematol.12948","volume":"93","author":"M Hunault-Berger","year":"2008","unstructured":"Hunault-Berger, M. et al. Changes in antithrombin and fibrinogen levels during induction chemotherapy with L-asparaginase in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Use of supportive coagulation therapy and clinical outcome: the CAPELAL study. Haematologica 93, 1488\u20131494, doi: 10.3324\/haematol.12948 (2008).","journal-title":"Haematologica"},{"key":"BFsrep39463_CR52","doi-asserted-by":"publisher","first-page":"5146","DOI":"10.1182\/blood-2009-07-231084","volume":"114","author":"LS Abbott","year":"2009","unstructured":"Abbott, L. S. et al. The impact of prophylactic fresh-frozen plasma and cryoprecipitate on the incidence of central nervous system thrombosis and hemorrhage in children with acute lymphoblastic leukemia receiving asparaginase. Blood 114, 5146\u20135151, doi: 10.1182\/blood-2009-07-231084 (2009).","journal-title":"Blood"},{"key":"BFsrep39463_CR53","first-page":"1346","volume":"90","author":"JM Ribera","year":"2005","unstructured":"Ribera, J. M. et al. Comparison of intensive chemotherapy, allogeneic or autologous stem cell transplantation as post-remission treatment for adult patients with high-risk acute lymphoblastic leukemia. Results of the PETHEMA ALL-93 trial. Haematologica 90, 1346\u20131356 (2005).","journal-title":"Haematologica"},{"key":"BFsrep39463_CR54","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1200\/JCO.1993.11.10.1990","volume":"11","author":"D Fiere","year":"1993","unstructured":"Fiere, D. et al. Adult acute lymphoblastic leukemia: a multicentric randomized trial testing bone marrow transplantation as postremission therapy. The French Group on Therapy for Adult Acute Lymphoblastic Leukemia. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 11, 1990\u20132001 (1993).","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"key":"BFsrep39463_CR55","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/S0889-8588(05)70190-8","volume":"14","author":"A Thiebaut","year":"2000","unstructured":"Thiebaut, A. et al. Adult acute lymphocytic leukemia study testing chemotherapy and autologous and allogeneic transplantation. A follow-up report of the French protocol LALA 87. Hematology\/oncology clinics of North America 14, 1353\u20131366, x (2000).","journal-title":"Hematology\/oncology clinics of North America"},{"key":"BFsrep39463_CR56","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1200\/JCO.1994.12.12.2580","volume":"12","author":"C Sebban","year":"1994","unstructured":"Sebban, C. et al. Allogeneic bone marrow transplantation in adult acute lymphoblastic leukemia in first complete remission: a comparative study. French Group of Therapy of Adult Acute Lymphoblastic Leukemia. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 12, 2580\u20132587 (1994).","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"key":"BFsrep39463_CR57","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1182\/blood-2012-11-466482","volume":"122","author":"F Ravandi","year":"2013","unstructured":"Ravandi, F. et al. Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy. Blood 122, 1214\u20131221, doi: 10.1182\/blood-2012-11-466482 (2013).","journal-title":"Blood"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep39463.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep39463","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep39463.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T01:23:12Z","timestamp":1672881792000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep39463"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,21]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,12,23]]}},"alternative-id":["BFsrep39463"],"URL":"https:\/\/doi.org\/10.1038\/srep39463","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,21]]},"assertion":[{"value":"13 September 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"39463"}}